WASHINGTON, D.C. – The U.S. Food and Drug Administration (FDA) has approved Moderna’s mFlusiva (mRNA-1010), marking the nation’s first mRNA-based seasonal influenza vaccine for adults ages 50 and older.
Key Details & Advantages
- Superior Efficacy: In a global Phase 3 clinical trial involving more than 40,000 participants, mFlusiva demonstrated approximately 27% greater effectiveness in preventing laboratory-confirmed flu cases than traditional standard-dose influenza vaccines.
- Faster Production Timelines: Unlike conventional flu shots—which rely on egg- or cell-based manufacturing and require strain selection up to six months in advance—mRNA technology allows manufacturers to adjust vaccine targets much closer to the start of flu season. This significantly improves the odds of a precise match with actively circulating viral strains.
- Targeted Rollout: Moderna plans to make mFlusiva available nationwide for the upcoming 2026–2027 respiratory virus season, which typically begins in October.
Regulatory Path & Additional Context
- Approval Framework: The FDA granted full approval for adults ages 50 to 64, alongside an accelerated approval for individuals 65 and older. To maintain clearance for the older demographic, Moderna will conduct a post-marketing study to confirm comparative clinical benefits against high-dose influenza vaccines.
- Safety Profile: No new or serious safety concerns were identified during clinical testing. Reported side effects were mild to moderate, including localized injection-site pain, fatigue, and muscle aches, consistent with those observed with standard mRNA formulations.
- Broader Applications: The approval represents Moderna’s fourth FDA-cleared product and paves the way for potential combination vaccines currently in development, such as joint influenza and COVID-19 mRNA boosters.
